IMA: Koefisien rega marang pendapatan Ikena Oncology, Inc.
Optimized raw material delivery channels minimize supply chain disruption risks for ImageneBio Inc (IMA). Business revenues are based on bringing targeted oncology therapies to market. The synergy between biomarker discovery and drug development determines the dynamics of the enterprise value-to-revenue ratio, where the indicator value is 0.00. This chart allows for an assessment of the fairness of the stock's market price through the lens of real cash flows.
Rincian analitis perusahaan ImageneBio Inc (IMA)
- kuotasi saiki lan rata-rata prakiraan nilai:
- informasi kapitalisasi pasar:
- rincian nilai buku perusahaan:
- indikator beban kredit lan likuiditas emiten:
Rasio Utang marang Modal ImageneBio Inc|IMA - Utang jangka dawa marang modal|Kewajiban jangka cendhak marang modal ikenaoncology.com|IMA - Utang perusahaan|Rasio utang marang nilai buku Ikena Oncology, Inc.|IMA - Utang jangka dawa perusahaan|Utang jangka cendhak Ikena Oncology|Likuiditas cepet ikenaoncology.com
- data bathi bisnis lan rasio investasi:
IMA - Bathi resik|Prakiraan bathi perusahaan ImageneBio Inc|IMA - Rasio rega marang bathi|Rasio prakiraan rega marang bathi ikenaoncology.com|IMA - Pangali rega marang bathi tumrap wutah|Nilai bisnis marang bathi operasional sadurunge panyusutan Ikena Oncology, Inc.|IMA - Bathi operasional EBITDA|Bathi resik saben saham sajrone patang kuartal pungkasan Ikena Oncology|IMA - Bathi saben saham sajrone rolas wulan pungkasan|Wutah bathi saben saham taun-ka-taun sajrone 12 wulan pungkasan ikenaoncology.com|IMA - Wutah bathi ing taun lumaku|Prakiraan wutah bathi saben saham kanggo taun ngarep ImageneBio Inc
- rincian pendapatan lan dodolan emiten:
Analisis fundamental perusahaan:ImageneBio (IMA)
In the biopharmaceutical sector, ImageneBio Inc (IMA) focuses on the validation of oncology targets, delegating costly production stages to major partners. The P/S ratio reflects the relationship between market capitalization and sales volume, demonstrating the valuation's sensitivity to operational successes. This indicator measures the cost of each unit of revenue, making it possible to determine the extent of the premium paid for future growth. Analysis via the price-to-sales valuation reveals abnormal spikes in capitalization, signaling potential risks or entry points.
Perusahaan pesaing
ARGX - Rega marang dodolan|Multiplikator P/S BNTX (BioNTech)|Koefisien rega marang pendapatan Abivax Pharma (ABVX)|ADMA - Rasio rega marang pendapatan|Protagonist Corp (PTGX) - Kapitalisasi marang pendapatan|IMVT: Multiplikator P/S|kiniksa.com (KNSA) - Multiplikator P/S|GRFS (Grifols) - Multiplikator P/S|ADPT - Multiplikator rega marang pendapatan|Multiplikator P/S CLDX|AUPH - Rega marang dodolan|Rasio rega marang pendapatan BioCryst BCRX|VERA: Rasio kapitalisasi marang pendapatan|Dianthus Therapeutics, Inc. - Multiplikator P/S|Rega marang dodolan Pharvaris NV|ABCL: Multiplikator P/S|TRML (Tourmaline) - Rasio rega marang pendapatan|PGEN (Precigen, Inc.) - Multiplikator P/S|pharming.com (PHAR) - Koefisien rega marang pendapatan|Rasio rega marang pendapatan Nektar Therapeutics Inc. (NKTR)|UPB - Rega marang dodolan|Zenas Biopharma, Inc. - Kapitalisasi marang pendapatan|Rasio kapitalisasi pasar marang pendapatan IMNM|Gossamer Bio, Inc. - Multiplikator P/S|Koefisien rega marang pendapatan kalvista.com KALV|Septerna (SEPN) - Rasio rega marang pendapatan|Rasio kapitalisasi marang pendapatan PVLA|SVRA (Savara Corp) - Multiplikator P/S|Kapitalisasi marang pendapatan Rigel Corp (RIGL)|Multiplikator P/S ANAB|Koefisien rega marang pendapatan astriatx.com|Rasio rega marang pendapatan enGene ENGN|RAPT - Kapitalisasi marang pendapatan|Aerovate - Multiplikator P/S|ACRS - Multiplikator P/S|Kyverna Therapeutics (KYTX) - Rasio rega marang pendapatan|Rasio rega marang dodolan TLSA (tizianalifesciences.com)|CABA (Cabaletta Bio) - Multiplikator P/S|VTYX: Rasio kapitalisasi pasar marang pendapatan|Multiplikator P/S THTX|Multiplikator P/S Avalo Therapeutics Inc (AVTX)|Rasio rega marang pendapatan Eledon Pharmaceuticals ELDN|Rasio kapitalisasi pasar marang pendapatan AGEN|CLYM - Rasio rega marang pendapatan|Zura Bio Ltd (ZURA) - Kapitalisasi marang pendapatan|ATYR: Multiplikator P/S|Adagene Inc. (ADAG) - Multiplikator P/S|Kapitalisasi marang pendapatan STTK|EQ: Rasio kapitalisasi pasar marang pendapatan|Multiplikator P/S CNTB|Koefisien rega marang pendapatan immunic-therapeutics.com|Rasio rega marang pendapatan Atara Bio ATRA|IFRX - Kapitalisasi marang pendapatan|XFOR - Rasio rega marang pendapatan|Adicet Bio (ACET) - Kapitalisasi marang pendapatan|CELU (celularity.com) - Kapitalisasi marang pendapatan|INmune Bio Inc (INMB) - Multiplikator P/S|Rasio rega marang pendapatan Barinthus Bio|Rasio kapitalisasi marang pendapatan KZR (Kezar Life Sciences Inc)|Multiplikator P/S SABS|AKTX - Rega marang dodolan|Multiplikator P/S ENLV (Enlivex Therapeutics Ltd.)|Koefisien rega marang pendapatan Q32 Bio Inc (QTTB)|GOVX - Rasio rega marang pendapatan|Edesa Biotech Corp (EDSA) - Kapitalisasi marang pendapatan|IBIO: Multiplikator P/S|Carisma Therapeutics Inc. (CARM) - Multiplikator P/S|XTLB (XTL Biopharmaceuticals Ltd.) - Multiplikator P/S|BOLT - Multiplikator rega marang pendapatan|Multiplikator P/S HCWB|APVO - Rega marang dodolan|Rasio rega marang pendapatan AIM ImmunoTech Inc. AIM|ADTX: Rasio kapitalisasi marang pendapatan|GRI Bio - Multiplikator P/S|Rega marang dodolan XORTX Therapeutics Inc|HIND: Multiplikator P/S|REVB (Revelation Biosciences Corp) - Rasio rega marang pendapatan|INDP (Indaptus Therapeutics) - Multiplikator P/S|scinai.com (SCNI) - Koefisien rega marang pendapatan|Rasio rega marang pendapatan CalciMedica, Inc. (CALI)|AFMD - Rega marang dodolan|Allakos - Kapitalisasi marang pendapatan|Rasio kapitalisasi pasar marang pendapatan HOOK|IGM Bio - Multiplikator P/S|Koefisien rega marang pendapatan iteostherapeutics.com ITOS|Ocean Biomedical (OCEA) - Rasio rega marang pendapatan|Rasio kapitalisasi marang pendapatan TCBP|THRD (Third Harmonic Bio, Inc) - Multiplikator P/S
